|
Dietary protein source | Enzyme used to produce peptides | Peptide sequence or molecular weight | Object | IC50/EC50 values | Activity/mechanisms of action | Reference |
|
Pea protein | Thermolysin | <3 kDa | SHR and clinical trial | — | Peptides (100 and 200 mg/kg BW) reduced SBP | [140] |
Casein | — | VPP and IPP | Clinical trial | — | VPP and IPP improved central blood pressure and arterial stiffness | [81] |
Pistachio kernel | Pepsin and trypsin | ACKEP | ACE inhibition assay | ACE IC50 126 μM | ACKEP inhibited ACE by binding with ACE active site | [88] |
Chum salmon (Oncorhynchus keta) skin | Trypsin | GLPLNLP | ACE inhibition assay and SHRs | ACE IC50 18.7 μM | GLP exhibited ACE inhibition and antihypertensive effect by decreasing SBP | [94] |
Skate (Okamejei kenojei) skin | Alcalase and protease | LGPLGHQ and MVGSAPGVL | ACE inhibition assay and SHRs | ACE IC50 3.09–4.22 μM | Peptides inhibited ACE and decreased SBP and inhibited vasoconstriction via PPAR-γ expression, activation, and phosphorylation of eNOS in lungs | [95] |
Egg white ovotransferrin | Thermolysin and pepsin | IQW and LKP | SHRs | — | Peptides reduced mean blood pressure | [22] |
Cuttlefish (Sepia officinalis) muscle | Crude enzymes from B. mojavensis and cuttle fish hepatopancreas | VELYP, AFVGYVLP, and EKSYELP | ACE inhibition assay and SHRs | ACE IC50 5.22 μM | VELYP showed strong ACE inhibition through a noncompetitive inhibition and had antihypertensive effects by decreasing SBP | [96] |
Potato and rapeseed | Alcalase and potato autolysis | SLVSPSAAAAAAPGGS and KKRSKKKSFG | Goldblatt rat with hypertension and ACE inhibition | ACE IC50 324 μg/mL and 156 μg/mL | Peptides inhibited ACE and exhibited antihypertensive effects by reducing SBP | [85] |
Rice bran protein | Trypsin | YSK | ACE inhibition assay | ACE IC50 76 mM | YSK showed ACE inhibition through the formation of hydrogen bonds with active pockets of human ACE | [1] |
Sipuncula (Phascolosoma esculenta) | Pepsin and trypsin | RYDF, YASGR and GNGSGYVSR | ACE inhibition assay and SHRs | ACE IC50 235 μM, 185 μM, and 29 μM | Three peptides inhibited ACE noncompetitively. GNGSGYVSR (5 mg/kg BW) showed antihypertensive effect by decreasing SBP | [97] |
Lentil seeds (Lens culinaris var.) | Savinase | LLSGTQNQPSFLSGF, NSLTLPILRYL, and TLEPNSVFLPVLLH | ACE inhibition assay | ACE IC50 44–120 μM | Inhibited ACE through interaction by hydrogen bonds with three ACE residues of the catalytic site | [91] |
Bighead carp muscle | Pepsin | YNLKERYAAW and YNRLPEL | ACE inhibition assay | ACE IC50 1.35–3.42 μM | Peptides inhibited ACE activity | [98] |
Bovine casein | Pepsin and trypsin | YQKFPQYLQY | ACE inhibition assay and SHRs | ACE IC50 11.1 μM | Peptide inhibited ACE via competitive inhibition and exhibited antihypertension by decreasing SBP | [82] |
Hazelnut (Corylus heterophylla Fisch.) | Alcalase | AVKVL, YLVR, and TLVGR | ACE inhibition assay and SHRs | ACE IC50 15.42–249.3 μM | Peptides inhibited ACE activity via a noncompetitive mode via the formation of cation–pi interactions and YLVR reduced SBP | [89] |
Egg white from ostrich | Alkaline hydrolysis | YV | ACE inhibition assay | ACE IC50 63.97 μg/mL | YV showed ACE inhibition by binding to S1 and S2 ACE pocket sites via hydrogen bonds | [93] |
Soybean | Pediococcus pentosaceus SDL1409 | EDEVSFSP, SRPFNL, RSPFNL, and ENPFNL | ACE inhibition assay | ACE IC50 0.131–0.811 mg/mL | Peptides inhibited ACE via essential N-terminal sequence and amino acid position | [84] |
Shrimp (Pandalus borealis) protein | — | — | Randomized, double-blind, placebo-controlled, 8-week clinical study | — | Peptides (1200 mg/d) reduced the blood pressure due to a reduction of angiotensin II levels | [79] |
Beef (Bos taurus coreanae) myofibrillar proteins | Alkaline-AK and papain | LIVGIIRCV | ACE inhibition assay and SHRs | — | Peptides (400 and 800 mg/kg BW) inhibited ACE by 74.29% and decreased SBP | [99] |
Milk | Fermented using L. delbrueckii QS306 | LPYPY | ACE inhibition assay | ACE IC50 12.87 μg/mL | LPYPY inhibited ACE with IC50 12.87 μg/mL | [80] |
Mung bean protein | Bromelain | LPRL, YADLVE, LRLESF, HLNVVHEN, and PGSGCAGTDL | ACE inhibition assay and SHRs | ACE IC50 5.39–1912 μM | Peptides showed ACE inhibition and reduced SBP | [90] |
Seahorse (Hippocampus abdominalis) | Protamex | APTL, CNVPLSP, and PWTPL | ACE inhibition assay and SHRs | ACE IC50 0.044 μM | Peptides exhibited antihypertension by lowering blood pressure via vasodilation and ACE inhibition | [92] |
Black cumin seed | α-Chymotrypsin | VTPVGVPK | ACE inhibition assay | ACE IC50 value 1.8 μM | VTPVGVPK inhibited ACE via a noncompetitive inhibition | [86] |
Quinoa protein | Chymotrypsin | QHPHGLGALCAAPPST | ACE inhibition assay | — | Peptide displayed ACE inhibition by binding to ACE active hotspots | [62] |
White turmeric, turmeric, and ginger proteins | Pepsin and trypsin | VTYM, RGPFH, AEPPR, GSGLVP, KM, SPV, CACGGV, DVDP, CGVGAA, HVVV, and RSC | ACE inhibition assay | ACE IC50 16.4–36.5 μM | Peptides showed ACE inhibition | [9] |
Coix prolamin | Pepsin | VDMF | ACE inhibition assay | ACE IC50 382.28 μM | VDMF reduced ACE and AT1R expression in AngII-injury HUVECs | [87] |
Wheat gluten | Alcalase and PaproA | SAGGYIW and APATPSFW | ACE inhibition assay | ACE IC50 0.002–0.036 mg/mL | Peptides and negatively charged amino acids inhibited ACE via modulating ionic and hydrophobic interactions on ACE catalytic sites | [83] |
|